

# Karl Herholz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6538664/publications.pdf>

Version: 2024-02-01

147  
papers

12,338  
citations

23879

60  
h-index

29333

108  
g-index

156  
all docs

156  
docs citations

156  
times ranked

14124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging Clinical Subtypes and Associated Brain Networks in Alzheimer's Disease. <i>Brain Sciences</i> , 2022, 12, 146.	1.1	4
2	Amyloid-PET-Positive Patient With bvFTD. <i>Neurology: Clinical Practice</i> , 2021, 11, e952-e955.	0.8	4
3	Hide-and-seek for radiotracers and neurodegenerative pathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1791-1792.	3.3	0
4	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	4.9	254
5	Association of plasma YKL-40 with brain amyloid- $\beta^2$ levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	1.5	18
6	Competencies and training of radiographers and technologists for PET/MR imaging - a study from the UK MR-PET network. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 1.	0.6	10
7	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-26.	0.9	5
8	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 69-73.	1.2	13
9	Dual-phase [18F]florbetapir in frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 304-311.	3.3	18
10	[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 657-662.	0.5	24
11	Evaluation of the Benefit of Partial Volume Correction for High Resolution PET Scanners. , 2019, , .		0
12	Astrocyte Biomarkers in Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2019, 25, 77-95.	3.5	203
13	PET and MRI in gliomas: progress and perspectives. <i>Clinical and Translational Imaging</i> , 2018, 6, 73-75.	1.1	1
14	Spread of tau deposits: can we trust in vivo findings?. <i>Brain</i> , 2018, 141, 10-12.	3.7	4
15	Revolution of Alzheimer Precision Neurology. <i>Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease</i> , 2018, 64, S47-S105.	1.2	122
16	Functional neuroanatomical associations of working memory in early-onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 176-184.	1.3	10
17	Metabolic regional and network changes in Alzheimer's disease subtypes. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1796-1806.	2.4	23
18	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , 2018, 18, 289.	1.1	25

#	ARTICLE	IF	CITATIONS
19	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	3.0	48
20	Microglial activation in normal-appearing brain regions of patients with cerebral glioma: a cross-sectional study. <i>Lancet, The</i> , 2017, 389, S92.	6.3	1
21	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 183-195.	1.5	85
22	Clinical validity of presynaptic dopaminergic imaging with <sup>123</sup> I-ioflupane and noradrenergic imaging with <sup>123</sup> I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 228-242.	1.5	34
23	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 214-227.	1.5	67
24	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , 2017, 16, 661-676.	4.9	464
25	Brain Tumors: An Update on Clinical PET Research in Gliomas. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 5-17.	2.5	57
26	Validation of a realistic simulation of the HRRT using SimSET. , 2017, , .		1
27	Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer's disease: metabolic basis for dementia. <i>Scientific Reports</i> , 2016, 6, 27524.	1.6	68
28	An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy. <i>British Journal of Psychiatry</i> , 2016, 208, 491-496.	1.7	12
29	Tau PET and tauopathies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1684-1685.	3.3	7
30	TSPO expression in brain tumours: is TSPO a target for brain tumour imaging?. <i>Clinical and Translational Imaging</i> , 2016, 4, 145-156.	1.1	57
31	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	1.2	34
32	<sup>18</sup> F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 386-391.	2.8	41
33	The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An <sup>11</sup> C-( <i>R</i> )PK11195 PET Imaging and Neuropathology Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 512-517.	2.8	77
34	Amyloid imaging for dementia in clinical practice. <i>BMC Medicine</i> , 2015, 13, 163.	2.3	44
35	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 101-109.	0.6	14
36	Regional Neuronal Network Failure and Cognition in Late-Onset Sporadic Alzheimer Disease. <i>American Journal of Neuroradiology</i> , 2014, 35, S18-S30.	1.2	13

#	ARTICLE	IF	CITATIONS
37	<sup>18</sup> F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias. Journal of Nuclear Medicine, 2014, 55, 1959-1965.	2.8	172
38	The role of PET quantification in neurological imaging: FDG and amyloid imaging in dementia. Clinical and Translational Imaging, 2014, 2, 321-330.	1.1	13
39	Glomas. , 2014, , 863-880.		0
40	[11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1406-1419.	3.3	55
41	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 104-114.	3.3	170
42	FDG PET in dementia multicenter studies and clinical trials. Clinical and Translational Imaging, 2013, 1, 261-270.	1.1	8
43	Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease. Expert Review of Neurotherapeutics, 2013, 13, 1235-1245.	1.4	51
44	Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease. Brain Research, 2013, 1504, 16-24.	1.1	43
45	Imaging markers for Alzheimer disease. Neurology, 2013, 81, 487-500.	1.5	204
46	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.4	51
47	Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with 18F-FAHA. NeuroImage, 2013, 64, 630-639.	2.1	42
48	[18F]DPA-714: Direct Comparison with [11C]PK11195 in a Model of Cerebral Ischemia in Rats. PLoS ONE, 2013, 8, e56441.	1.1	77
49	Staging of the cognitive decline in Alzheimer's disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer's disease. International Journal of Geriatric Psychiatry, 2012, 27, 423-432.	1.3	42
50	SNM Practice Guideline for Dopamine Transporter Imaging with <sup>123</sup> I-Ioflupane SPECT 1.0. Journal of Nuclear Medicine, 2012, 53, 154-163.	2.8	199
51	[11C]-MP4A PET Cholinergic Measurements in Amnesic Mild Cognitive Impairment, Probable Alzheimer's Disease, and Dementia with Lewy Bodies: A Bayesian Method and Voxel-Based Analysis. Journal of Alzheimer's Disease, 2012, 31, 387-399.	1.2	41
52	Summary Metrics to Assess Alzheimer Disease-Related Hypometabolic Pattern with <sup>18</sup> F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	2.8	79
53	Effectiveness and Safety of <sup>18</sup> F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature. Journal of Nuclear Medicine, 2012, 53, 59-71.	2.8	251
54	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. Advances in Biological Psychiatry, 2012, , 80-114.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Imaging cerebral amyloid plaques: clinical perspective. <i>Lancet Neurology</i> , The, 2012, 11, 652-653.	4.9	4
56	Cholinergic system function and cognition in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 867-877.	1.5	96
57	Brain Tumors. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 356-370.	2.5	129
58	Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2012, 6, 431-439.	0.6	41
59	Brain inflammation is induced by co-morbidities and risk factors for stroke. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1113-1122.	2.0	173
60	Perfusion SPECT and FDG-PET. <i>International Psychogeriatrics</i> , 2011, 23, S25-S31.	0.6	41
61	Optimized Data Preprocessing for Multivariate Analysis Applied to <sup>99m</sup> Tc-ECD SPECT Data Sets of Alzheimer's Patients and Asymptomatic Controls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 371-383.	2.4	24
62	Clinical amyloid imaging in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2011, 10, 667-670.	4.9	217
63	Early signs of VCP-related frontotemporal dementia: a neuropsychological, FDG-PET and fMRI study. <i>Journal of Neurology</i> , 2011, 258, 515-518.	1.8	3
64	Evaluation of a Calibrated <sup>18</sup> F-FDG PET Score as a Biomarker for Progression in Alzheimer Disease and Mild Cognitive Impairment. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1218-1226.	2.8	101
65	Molecular Imaging in Alzheimer's Disease. <i>European Neurological Review</i> , 2011, 6, 16.	0.5	1
66	Amino acid PET and clinical management of glioma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 683-684.	3.3	7
67	[ <sup>11</sup> C]-l-Methionine positron emission tomography in the management of children and young adults with brain tumors. <i>Journal of Neuro-Oncology</i> , 2010, 96, 231-239.	1.4	63
68	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 560-574.	21.5	560
69	Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1667-1673.	1.4	117
70	<sup>5</sup> -123I-A-85380 binding to the $\alpha 4\beta 2$ -nicotinic receptor in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 1885-1893.	1.5	24
71	Methyl-l- <sup>11</sup> C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1962-1968.	2.8	88
72	On the multivariate nature of brain metabolic impairment in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 186-197.	1.5	52

#	ARTICLE	IF	CITATIONS
73	Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 25-29.	3.3	71
74	Deficits of the cholinergic system in early AD. <i>Neuropsychologia</i> , 2008, 46, 1642-1647.	0.7	35
75	Multicenter Standardized <sup>18</sup> F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias. <i>Journal of Nuclear Medicine</i> , 2008, 49, 390-398.	2.8	637
76	Cortical Flattening Applied to High-Resolution <sup>18</sup> F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 44-49.	2.8	3
77	Evaluation of Primary Brain Tumors Using <sup>11</sup> C-Methionine PET with Reference to a Normal Methionine Uptake Map. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1971-1980.	2.8	47
78	Prefrontal cortex dysfunction and depression in atypical parkinsonian syndromes. <i>Movement Disorders</i> , 2007, 22, 490-497.	2.2	32
79	Metabolic and molecular imaging in neuro-oncology. <i>Lancet Neurology</i> , The, 2007, 6, 711-724.	4.9	100
80	Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia. <i>NeuroImage</i> , 2006, 30, 871-878.	2.1	43
81	Cognitive dysfunction and emotional behavioural changes in MS: The potential of positron emission tomography. <i>Journal of the Neurological Sciences</i> , 2006, 245, 9-13.	0.3	8
82	Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. <i>Neuroscience Letters</i> , 2006, 408, 46-50.	1.0	37
83	<sup>18</sup> F-FDG PET in Vascular Dementia: Differentiation from Alzheimer's Disease Using Voxel-Based Multivariate Analysis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 1213-1221.	2.4	106
84	Use of <sup>11</sup> C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 516-524.	3.3	132
85	From the left to the right: How the brain compensates progressive loss of language function. <i>Brain and Language</i> , 2006, 98, 57-65.	0.8	157
86	Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease. <i>Human Brain Mapping</i> , 2006, 27, 588-597.	1.9	157
87	Orbitofrontal Dysfunction Related to Both Apathy and Disinhibition in Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 373-379.	0.7	172
88	Brain receptor imaging. <i>Journal of Nuclear Medicine</i> , 2006, 47, 302-12.	2.8	133
89	Cerebral acetylcholine esterase activity in mild cognitive impairment. <i>NeuroReport</i> , 2005, 16, 1431-1434.	0.6	60
90	Crossed Cerebellar Diaschisis in Acute Human Stroke: A PET Study of Serial Changes and Response to Supratentorial Reperfusion. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1685-1691.	2.4	94

#	ARTICLE	IF	CITATIONS
91	Reduced glucose metabolism in temporo-parietal cortices of women with borderline personality disorder. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 115-126.	0.9	58
92	Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease. <i>Archives of Neurology</i> , 2005, 62, 1728.	4.9	269
93	Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease—Reply. <i>Archives of Neurology</i> , 2005, 62, 1480.	4.9	1
94	Nonlinear Progression of Parkinson Disease as Determined by Serial Positron Emission Tomographic Imaging of Striatal Fluorodopa F 18 Activity. <i>Archives of Neurology</i> , 2005, 62, 378.	4.9	268
95	Neuroimaging-guided rTMS of the left inferior frontal gyrus interferes with repetition priming. <i>NeuroImage</i> , 2005, 25, 815-823.	2.1	40
96	Imaging in neurooncology. <i>NeuroRx</i> , 2005, 2, 333-347.	6.0	154
97	Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. <i>Biological Psychiatry</i> , 2005, 57, 412-421.	0.7	168
98	Modelling focal brain lesions: Perfusion changes induced by rTMS over language related cortex. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S356-S356.	2.4	0
99	Imaging in neurooncology. <i>Neurotherapeutics</i> , 2005, 2, 333-347.	2.1	1
100	18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1948-58.	2.8	180
101	Subthalamic Nucleus Stimulation Restores Glucose Metabolism in Associative and Limbic Cortices and in Cerebellum: Evidence from a FDG-PET Study in Advanced Parkinson's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 7-16.	2.4	192
102	Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study. <i>Psychiatry Research - Neuroimaging</i> , 2004, 130, 141-151.	0.9	39
103	Delineation of Brain Tumor Extent with [11C]-Methionine Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2004, 10, 7163-7170.	3.2	286
104	Positron emission tomography in clinical neurology. <i>Molecular Imaging and Biology</i> , 2004, 6, 239-269.	1.3	86
105	Fast and robust registration of PET and MR images of human brain. <i>NeuroImage</i> , 2004, 22, 434-442.	2.1	147
106	Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. <i>Journal of Nuclear Medicine</i> , 2004, 45, 382-92.	2.8	58
107	Metabolic rates in small brain nuclei determined by high-resolution PET. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1811-5.	2.8	54
108	Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 868-873.	3.3	181

#	ARTICLE	IF	CITATIONS
109	PET studies in dementia. <i>Annals of Nuclear Medicine</i> , 2003, 17, 79-89.	1.2	207
110	Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. <i>Human Brain Mapping</i> , 2003, 18, 13-21.	1.9	115
111	Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. <i>NeuroImage</i> , 2003, 20, 435-440.	2.1	120
112	The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. <i>Journal of Chemical Neuroanatomy</i> , 2003, 26, 293-299.	1.0	521
113	The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. <i>Neuroscience Letters</i> , 2002, 323, 50-54.	1.0	74
114	Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. <i>Journal of Nuclear Medicine</i> , 2002, 43, 21-6.	2.8	114
115	Activation of thalamo-cortical systems in post-traumatic flashbacks: A positron emission tomography study. <i>Traumatology</i> , 2001, 7, 131-141.	1.6	6
116	Increased pineal Fdopa uptake is related to severity of Parkinson's disease - A PET study. <i>Journal of Pineal Research</i> , 2001, 30, 213-219.	3.4	24
117	Learning face-name associations and the effect of age and performance: a PET activation study. <i>Neuropsychologia</i> , 2001, 39, 643-650.	0.7	42
118	Functional Imaging Correlates of Recovery after Stroke in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 1619-1631.	2.4	53
119	Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. <i>Journal of Neurology</i> , 1999, 246, 198-206.	1.8	73
120	Positron Emission Tomography in a Case of Intracranial Hemangiopericytoma. <i>Journal of Computer Assisted Tomography</i> , 1999, 23, 365-368.	0.5	23
121	Functional Amnesia and Memory Consolidation: A Case of Severe and Persistent Anterograde Amnesia with Rapid Forgetting Following Whiplash Injury. <i>Neurocase</i> , 1999, 5, 189-199.	0.2	3
122	Collateral Inhibition of Transcallosal Activity Facilitates Functional Brain Asymmetry. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 1157-1161.	2.4	57
123	Cerebral Networks and Functional Brain Asymmetry: Evidence from Regional Metabolic Changes during Word Repetition. <i>Brain and Language</i> , 1998, 63, 108-121.	0.8	32
124	Localization of Language-Related Cortex with <sup>15</sup> O-Labeled Water PET in Patients with Gliomas. <i>NeuroImage</i> , 1998, 7, 284-295.	2.1	97
125	Brain Plasticity in Poststroke Aphasia: What Is the Contribution of the Right Hemisphere?. <i>Brain and Language</i> , 1998, 64, 215-230.	0.8	261
126	Preoperative Activation and Intraoperative Stimulation of Language-related Areas in Patients with Glioma. <i>Neurosurgery</i> , 1997, 41, 1253-1262.	0.6	157



#	ARTICLE	IF	CITATIONS
127	Speech-induced cerebral metabolic activation reflects recovery from aphasia. <i>Journal of the Neurological Sciences</i> , 1997, 145, 213-217.	0.3	154
128	Performance of a Randomization Test for Single-Subject 15O-Water PET Activation Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 1033-1039.	2.4	15
129	Diagnostic imaging of dementia in the elderly. <i>Archives of Gerontology and Geriatrics</i> , 1997, 25, 5-12.	1.4	1
130	Permutation test analysis of functional 15O-H2O-PET brain images: Application to single-subject speech activation studies. <i>NeuroImage</i> , 1996, 3, S63.	2.1	1
131	Clinical applications of registration and fusion of multimodality brain images from PET, SPECT, CT, and MRI. <i>European Journal of Radiology</i> , 1996, 21, 174-182.	1.2	72
132	Neuroimaging in anorexia nervosa. <i>Psychiatry Research</i> , 1996, 62, 105-110.	1.7	46
133	Regional Cerebral Blood Flow and Metabolism in Sturge-Weber Disease. <i>Clinical Nuclear Medicine</i> , 1995, 20, 522-523.	0.7	19
134	Assessment of pathophysiology of stroke by positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 455-65.	2.2	41
135	HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 1052-60.	2.2	115
136	Difference of regional cerebral metabolic pattern between presenile and senile dementia of the Alzheimer type: A factor analytic study. <i>Journal of the Neurological Sciences</i> , 1994, 123, 11-17.	0.3	41
137	Transcranial doppler and 15O-H2O-positron emission tomography findings in patients with acute brain infarction and middle cerebral artery stenosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 1994, 4, 23-29.	0.7	0
138	Positron emission tomography in myotonic dystrophy. <i>Psychiatry Research - Neuroimaging</i> , 1993, 50, 93-99.	0.9	18
139	Peri-Infarct perfusion in human ischemia: Its relation to tissue metabolism, morphology, and clinical outcome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 1993, 3, 123-131.	0.7	16
140	Correlation of glucose consumption and tumor cell density in astrocytomas. <i>Journal of Neurosurgery</i> , 1993, 79, 853-858.	0.9	130
141	FDG-PET as a Prognostic Indicator in Radiochemotherapy of Glioblastoma. <i>Journal of Computer Assisted Tomography</i> , 1993, 17, 681-687.	0.5	84
142	Functional and morphological imaging of small striato-capsular infarction by CT, MRI and multitracer PET. <i>Neurological Research</i> , 1992, 14, 139-142.	0.6	2
143	FDG transport and phosphorylation in human gliomas measured with dynamic PET. <i>Journal of Neuro-Oncology</i> , 1992, 12, 159-65.	1.4	58
144	Positron emission tomography findings in dementia disorders: Contributions to differential diagnosis and objectivizing of therapeutic effects.. <i>Keio Journal of Medicine</i> , 1989, 38, 111-135.	0.5	21

#	ARTICLE	IF	CITATIONS
145	Non-stationary spatial filtering and accelerated curve fitting for parametric imaging with dynamic PET. European Journal of Nuclear Medicine and Molecular Imaging, 1988, 14, 477-484.	2.2	28
146	Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET. European Journal of Cancer & Clinical Oncology, 1988, 24, 1139-1150.	0.9	19
147	Comparative Regional Analysis of 2-Fluorodeoxyglucose and Methylglucose Uptake in Brain of Four Stroke Patients. With Special Reference to the Regional Estimation of the Lumped Constant. Journal of Cerebral Blood Flow and Metabolism, 1985, 5, 163-178.	2.4	171